314 related articles for article (PubMed ID: 33104165)
1. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society.
Miller AE; Chitnis T; Cohen BA; Costello K; Sicotte NL; Stacom R;
JAMA Neurol; 2021 Feb; 78(2):241-246. PubMed ID: 33104165
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
3. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
4. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
5. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
6. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
7. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
8. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
[TBL] [Abstract][Full Text] [Related]
9. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
[TBL] [Abstract][Full Text] [Related]
13. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
14. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP; Muraro PA; Saccardi R; Mancardi G
Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
[TBL] [Abstract][Full Text] [Related]
15. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
17. Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis.
Ross LA; Stropp LM; Cohen JA
Neurol Clin; 2024 Feb; 42(1):165-184. PubMed ID: 37980114
[TBL] [Abstract][Full Text] [Related]
18. NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Ruder J; Rex J; Obahor S; Docampo MJ; Müller AMS; Schanz U; Jelcic I; Martin R
Front Immunol; 2021; 12():794077. PubMed ID: 34975899
[TBL] [Abstract][Full Text] [Related]
19. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
[TBL] [Abstract][Full Text] [Related]
20. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
Willison AG; Meuth SG
Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
